Acitretin embryopathy: A case report

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 70, Issue 10, 2004, Pages 831-833

  Barbero, Pablo ^a   Lotersztein, Vanesa ^a   Bronberg, Ruben ^a   Perez, Miriam ^a   Alba, Liliana ^a  

^a Centro Nacional de Genetica Medica de Buenos Aires   (Argentina)

Author keywords

Acitretin; Embryopathy; Retinoic acid; Teratology

Indexed keywords

ETRETIN; ETRETINATE; ISOTRETINOIN; RETINOID DERIVATIVE; RETINOL DERIVATIVE; TERATOGENIC AGENT;

ANTEVERTED NOSTRIL; ARTICLE; CASE REPORT; EAR MALFORMATION; EMBRYOPATHY; EPICANTHUS; FEMALE; GESTATIONAL AGE; HEART ATRIUM SEPTUM DEFECT; HUMAN; INFANT; MICROCEPHALY; NERVE CELL DIFFERENTIATION; NOSE MALFORMATION; PALATE MALFORMATION; PERCEPTION DEAFNESS; PHENOTYPE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

ABNORMALITIES, MULTIPLE; ACITRETIN; EMBRYO; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; TERATOGENS;

EID: 8144223189     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.20078     Document Type: Article

References (16)

1. Blanchet-Bardon C, Nazzaro V, Rognin C, et al. 1991. Acitretin in the treatment of severe disorders of keratinization. Results of an open study. J Am Acad Dermatol 24:982-986.
2. Chou RC, Wyss R, Huselton CA, et al. 1991. A newly discovered xenobiotic metabolic pathway: ethyl ester formation. Life Sci 49:169-172.
3. de Die-Smulders CEM, Sturkenboom MCJM, Veraart J, et al. 1995. Severe limb defects and craniofacial abnormalities in a fetus conceived during acitretin therapy. Teratology 52:215-219.
4. Di Giovanna JJ, Zech LA, Rudell ME, et al. 1989. Etretinate: persistent serum levels after longterm therapy. Arch Dermatol 125:246-251.
5. Geiger JM, Baudin M, Saurat JH. 1994. Teratogenic risk with etretinate and acitretin treatment. Dermatology 189:109-116.
6. Grote W, Harms D, Jänig U, et al. 1985. Malformation of fetus conceived 4 months after termination of maternal etretinate treatment. Lancet 1:1276.
7. Happle R, Traupe H, Bounameaux Y, et al. 1984. Teratogenic effects of etretinate in humans. Dtsch Med Wochenschr 109:1476-1480.
8. Kistler A, Hummler H. 1985. Teratogenesis and reproductive safety evaluation of the retinoid etretin (Ro 10-1670). Arch Toxicol 58:50-56.
9. Lammer EJ, Chen DT, Hoar RM, et al. 1985. Retinoic acid embryopathy. N Engl J Med 313:837-841.
10. Larsen FG, Jakobsen P, Knudsen J, et al. 1993. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 100:623-627.
11. Lejarraga H, Fustinana C. 1986. Estándares de peso, longitud corporal y perímetro cefálico desde las 26 hasta las 92 semanas de edad postmenstrual. Arch Argent Pediatr 84:210-214.
12. Ling MR. 1999. Acitretin: optimal dosing strategies. J Am Acad Dermatol 41(3 Pt 2):S13-S17.
13. Maier H, Honigsmann H. 1996. Concentration of etretinate in plasma and subcutaneous fat after long-term acitretin. Lancet 348:1107.
14. Moerike S, Pantzar JT, De Sa D. 2002. Temporal bone pathology in fetuses exposed to isotretinoin. Pediatr Dev Pathol 5:405-409.
15. Paravicini U, Stockel K, McNamara P, et al. 1981. On metabolism and pharmacokinetics of an aromatic retinoid. Ann NY Acad Sci 359:54-67.
16. Westerman ST, Gilbert LM, Schondel L. 1994. Vestibular dysfunction in a child with embryonic exposure to accutane. Am J Otol 15:400-403.